Sofinnova sells Breath Therapeutics to Zambon

Sofinnova Partners said July 25 that it has sold Breath Therapeutics to Zambon for up to 500 million euros ($556.9 million), including 140 million euros up front. Breath Therapeutics provides inhalation therapies for severe respiratory diseases.

DealsNorth AmericaUSHealthcareBriefs